Ditto Biosciences
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Ditto Biosciences - overview
Established
2025
Location
San Francisco, CA, US
Primary Industry
Biotechnology
About
Founded in 2025, based in San Francisco, US, Ditto Biosciences is a biotechnology company focused on discovering new treatments for autoimmune diseases by harnessing parasite biology. The company uses genomics and artificial intelligence to identify and engineer parasite‑derived proteins that can modulate the human immune system. Co-founded by CEO Dennis Sun, CSO Adair Borges and CTO Emily Weiss. In March 2026, Ditto Biosciences raised an undisclosed amount of seed funding from new investor Pioneer Fund.
Ditto Bio develops an AI‑powered drug discovery platform that identifies therapeutic proteins from parasites and pathogens with potential applications in autoimmune diseases. Its work centers on discovering and engineering novel biologics rather than offering commercialized products at this stage. As an early‑stage biotechnology firm, Ditto Bio appears to be focused on research and development rather than near‑term commercialization. Ditto Bio plans to continue expanding its AI‑driven platform to systematically mine parasite biology for new autoimmune drug candidates.
Current Investors
Pioneer Fund
Primary Industry
Biotechnology
Sub Industries
Bioinformatics, Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy
Website
www.dittobio.com/
Verticals
Artificial Intelligence
Company Stage
Angel & Seed
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.